Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
NCT ID | NCT05687266 |
Title | Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations (AVANZAR) |
Acronym | AVANZAR |
Recruitment | Active, not recruiting |
Gender | both |
Phase | Phase III |
Variant Requirements | Yes |
Sponsors | AstraZeneca |
Indications | |
Therapies | |
Age Groups: | adult | senior |
Covered Countries | USA | TUR | SWE | POL | ITA | HUN | GRC | GBR | FRA | ESP | DEU | CAN | BRA | BGR | AUT |